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Abstract

Author Manuscript

A topoisomerase-DNA transient covalent complex can be a druggable target for novel
topoisomerase poison inhibitors that represent a new class of antibacterial or anticancer drugs.
Herein, we have investigated molecular features of the functionally important Escherichia coli
topoisomerase I (EctopoI)-DNA covalent complex (EctopoIcc) for molecular simulations, which is
very useful in the development of new antibacterial drugs. To demonstrate the usefulness of our
approach, we used a model small molecule (SM), NSC76027, obtained from virtual screening. We
examined the direct binding of NSC76027 to EctopoI as well as inhibition of EctopoI relaxation
activity of this SM via experimental techniques. We then performed molecular dynamics (MD)
simulations to investigate the dynamics and stability of EctopoIcc and EctopoI-NSC76027-DNA
ternary complex. Our simulation results show that NSC76027 forms a stable ternary complex with
EctopoIcc. EctopoI investigated here also serves as a model system for investigating a complex of
topoisomerase and DNA in which DNA is covalently attached to the protein.
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This report presents an approach to design functionally important covalent complex between
bacterial topoisomerase and DNA for molecular simulations, which is very useful in development
of new antibacterial drugs. Our results demonstrate the suitability of the model and procedures
employed in this report for computational studies of inhibitors targeting topoisomerases.
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Introduction

Author Manuscript

DNA topoisomerases are responsible for regulation of DNA topology, a crucial cellular
process, which is very important in replication, transcription and recombination.[1]
Topoisomerase I (topoI) cleaves and rejoins the single strand of DNA with a transient
covalent complex.[2] These covalent complexes can be trapped by topoisomerase poison
inhibitors.[3] Development of topoisomerase poison inhibitors have clinical applications as
antitumor[4] antiviral[5] and antibacterial drugs.[6]
Previous genetic studies showed that the accumulation of the topoI-DNA covalent cleavage
complexes (topoccs) in Escherichia coli can cause the bacterial cell death.[7] Bacterial DNA
topoI belonging to the type IA topoisomerase family maintains the genome stability[8] and
is a promising target biomolecule for antibacterial drug discovery[7a, 9] with E. coli
topoisomerase I (EctopoI) as the most extensively studied member of the type IA
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topoisomerase family.[10] In EctopoI, Y319 is the active site tyrosine, which is responsible
for the formation of transient covalent linkage with the 5’ phosphoryl group of cleaved
DNA.[11] In E. coli, EctopoI regulates the DNA supercoiling by removing excess negative
supercoils.[12] In recent years, bacterial pathogens have become more resistant to available
antibacterial drugs, thus becoming a serious public health issue. There is at least one type IA
topoI in each bacterium and a new class of poison inhibitors can be utilized to target these
topoisomerases.[7a] It is therefore highly desirable to identify the poison inhibitors for type
IA topoI for the development of new antibacterial drugs.[3, 7a, 9a] Development of such
new antibacterial drugs requires investigations of topoIccs.

Author Manuscript
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Computational approaches have proved to be very useful in structure based drug discovery,
including hit identification and lead optimization[13] as well as in investigating drug
specificity.[14] These computation-based approaches include docking[15] virtual screening
(VS)[16] and molecular dynamics (MD) simulations.[17] Despite development of many
docking algorithms, the results from these algorithms have limitations in the success of
binding predictions.[18] Computer-aided virtual screening can be used to predict ligand
binding to a receptor[19] but it has limitations in incorporating receptor flexibility.[20]
Binding of a drug molecule to its target, more importantly protein, is a dynamic process[17a]
and proteins are flexible biomolecules with a relatively small number of atoms in an average
residue.[21] The dynamic flexibility of protein biomolecules can be incorporated via allatom MD simulation[22], which is beneficial to explore drug targets.[23] Therefore,
complementing the docking or VS results with MD simulations can be an effective strategy
in the structure-based drug discovery.[18] However, MD simulations-aided investigations for
structure-based drug discovery of antibacterial drugs involving bacterial topoIccs are
lacking. This is mostly due to the difficulty in using the functionally important intermediate
topoI structure in molecular simulations because the intermediate structure consists of a
DNA fragment that is covalently complexed with the protein. In the past, MD simulationbased investigations of human topoisomerases (Htopos) in covalent complex with DNA
(Htopocc) have been carried out.[24] Nevertheless, the simulation parameters are not
provided for straightforward application without any optimizations and with no clear
evidence of the covalent complex formation. Here, we used available CGenFF force field
parameters to create linkage of EctopoI with the DNA single strand, providing an easy
option with more straightforward procedure, so that MD simulations can be carried out for
the EctopoI in covalent complex with DNA that has 5’ phosphodiester bond with tyrosine.
Our procedure provides an easy and straightforward option to create the DNA-protein
covalent linkage for computational investigations using CHARMM36m force field for MD
simulation-based investigations of the bacterial topoIccs with implications in antibacterial
drug discovery, for the first time to the best of our knowledge.
To demonstrate the usefulness of our approach in the new antibacterial drug development,
we used a model SM, NSC76027, obtained from a virtual screening (VS) of NCI DTP
library of small molecules (SMs). We used a minimized the covalent complex of EctopoI
with a single stranded DNA (ssDNA), referred to as EctopoIcc hereafter, as well as EctopoI
conformation, taken from the same EctopoIcc, as the screening targets. Our virtual screening
approach with both EctopoIcc and EctopoI alone will avoid toxic topoI inhibitors that bind
non-selectively to DNA. We examined the direct binding of NSC76027 to EctopoI as well
ChemMedChem. Author manuscript; available in PMC 2021 April 03.
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inhibition of EctopoI relaxation activity of this SM utilizing experimental techniques.
Surface plasmon resonance (SPR)-based experiments were performed to validate the direct
binding of NSC76027 to EctopoI. In vitro relaxation inhibition assay for NSC76027
confirmed its inhibition of EctopoI activity. We then performed MD simulations to
investigate the dynamics of the EctopoI-NSC76027-DNA complex (referred to as ternary
complex hereafter). In the ternary structure, we constructed a covalent bond between
EctopoI and a ssDNA using our procedure. Our approach is also useful in the MD
simulation-based studies of other type of topoccs, including HtopoI, a major target
biomolecule of anticancer agents.[25]

Results
EctopoI-DNA covalent complex and energy minimization

Author Manuscript

Figure 1 shows the covalent linkage of EctopoI with ssDNA from the minimized structure of
EctopoIcc. The dotted circle in the Figure 1 shows the phosphorylated EctopoI Y319 with
one of the side chain oxygen atoms (OS319) covalently linked with 5’ DNA carbon of thymine
in the 9th position (C5′
9 ). This model serves as the covalent complex between DNA

Author Manuscript

nucleotide and Y319. Our procedure is able to handle such a covalent linkage between
bacterial topoI and DNA and therefore can be used to explore interactions of this important
protein-DNA interaction. A topology file (TYDN.rtf) and a parameter file (TYDN.prm)
were used to generate and minimize the complex structure, respectively. These topology and
parameter files are given in the Supporting Information (Sections S1 and S2). Figure S1
shows a 2-D representation of the covalently bound EctopoI residue and ssDNA nucleotide
portions (Supporting Information, Section S1). To check usefulness of our approach in the
MD simulation-based studies of other type of topoIccs, we also created the HtopoIcc and
successfully minimized the covalent complex structure. Since the active site tyrosine, Y723,
[26] in HtopoI forms a covalent linkage with 3’ DNA, unlike Y319 in EctopoI forms
covalent complex with 5’ DNA, we needed to use a slightly different TYDN.rtf and
TYDN.prm files for 3’ DNA as given in the Supporting Information (Sections S1 and S2).
Virtual screening (VS)

Author Manuscript

We performed VS of NCI DTP library SMs taking the minimized EctopoIcc structure as a
target. We independently performed the screening of the same library of SMs against the
minimized EctopoI conformation as well. Notably, EctopoI coordinates used as the target
here was extracted from the same minimized EctopoIcc conformation. We selected 2263
soluble SMs from the library of 2642 total SMs. We examined docked position of SMs for
being near our target area, the Y319 cleavage site, as described in virtual screening
subsection of the Experimental section. We considered NSC76027, one of the top hit SMs
based on affinity obtained from VS that lie near the active site, as a model SM just to
demonstrate the usefulness of our approach in the new antibacterial drug development. This
SM has also been identified as SerB2 (phosphoserine phosphatase) enzyme inhibitor.[27]
Since we used minimized structures of EctopoIcc, we believe that this EctopoI reaction
intermediate enhances the significance of the screening results. In support of this approach
of employing the EctopoIcc, the loop and alpha helices near the NSC76027 binding site
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show significant structural variation between the EctopoI-DNA covalent and non-covalent
complex (PDB 1MW8[28]) with RMSD value of 4.0 Å (Figure S2, Supporting Information,
Section S3). Our procedure should therefore facilitate structure-based antibacterial drug
development targeting bacterial DNA topoisomerases. Our procedure is also applicable for
other DNA topoisomerases, including HtopoI.
Surface plasmon resonance (SPR)

Author Manuscript

We used SPR experiments to validate the selective direct binding of NSC76027 to EctopoI,
to examine whether NSC76027 shows concentration dependent binding to EctopoI, and to
determine equilibrium dissociation constant (KD) of the interaction. In the validation
experiment, we injected NSC76027 solution at 5 μM concentration over the CM5 sensor
surface. SPR sensorgrams demonstrating the selective binding of NSC76027, to EctopoI as
shown in Figure 2A. At 5 μM, NSC76027 binds to EctopoI with a response amplitude much
higher as compared to Ezrin, a control protein immobilized using identical surface chemistry
as for EctopoI on the same CM5 chip surface. The negative control analyte, NSC14975,
does not bind to the immobilized EctopoI. We then performed SPR-based dose response
assays for NSC76027. In the dose response assays, we independently immobilized EctopoI
and Ezrin on another CM5 chip in a similar fashion as in the selective binding tests. Both
analytes (NSC76027 and NSC14975) were serially diluted in buffer solutions. SPR
sensorgrams for NSC76027 binding to EctopoI in a concentration dependent manner are
shown in Figure 2B. The two continuous lines with same color indicate the technical
reproducibility of the SPR sensorgrams for the same concentrations recorded in duplicate.
We repeated NSC76027 dose response at least three times with different concentration range
of NSC76027. As expected, a control experiment with NSC14975 (negative control analyte)
exhibited no binding to EctopoI as shown in Figure 2C.

Author Manuscript
Author Manuscript

We further conducted SPR assays to determine the KD of NSC76027-EctopoI interaction. As
shown in Figure 2D, in the single cycle approach, various concentrations of the same analyte
(NSC76027) were injected one after another, in increasing concentrations in the same cycle
of the run. The experimental SPR sensorgrams (green continuous lines) were fitted to 1:1
kinetics binding model (dashed lines) to extract the KD of NSC76027-EctopoI binding and
we obtained a KD value of ~80 nM for the interaction. We also repeated kinetics
experiments two more times with multicycle kinetics with different NSC76027
concentration ranges. As expected, we obtained very similar KD values (79±8 nM, average
±s.d., from three experimental replicates) for the NSC76027-EctopoI interaction when
experimental data were fitted to the same 1:1 kinetics model. As expected, there is no dose
response for NSC76027 binding to Ezrin (blue continuous lines, Figure 2D) to determine KD
value by fitting. SPR experiments thus confirm selective direct binding of NSC76027 to
EctopoI as predicted by in silico VS. Moreover, the NSC76027-EctopoI binding is
concentration dependent with nanomolar affinity.
Relaxation inhibition assay
We carried out relaxation assays for inhibition of EctopoI relaxation activity in the presence
of NSC76027. In vitro relaxation inhibition assay also showed that NSC76027 was able to
inhibit the relaxation activity of EctopoI in a dose dependent manner (Figure 3A). As
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displayed in Figure 3B, NSC76027 inhibited 50% of the enzyme activity at ~2.2 μM (IC50
value). A relaxation inhibition assay with the negative control SM showed that NSC14975
does not inhibit the EctopoI relaxation activity even at 125 μM with 25 μM NSC76027 was
also used as the positive control, which completely inhibits the relaxation activity (Figure
3C). NSC76027 also inhibits the relaxation activity of M. tuberculosis topoI (MttopoI) with
an IC50 value of ~3.0 μM (data not shown).
Molecular dynamics (MD) simulations

Author Manuscript

The dynamics of the ternary complex was investigated using MD simulations taking the
optimized NSC76027 conformation (Supporting Information, Section S4). A movie of the
MD simulation (Supporting Information, Section S5) shows the dynamics of the ternary
complex. Notably, NSC76027 resides within the EctopoI-ssDNA binding interface, near the
ssDNA cleavage site. As depicted by RMSD measurements (Figure 4A), the overall ternary
complex structure was stable after ~40 ns of the simulation time. Figure 4B shows the radius
of gyration (Rg) measurement of the ternary complex. The measurements of Rg further
demonstrate the thermal stability of the ternary complex after ~40 ns of the simulation time.
For comparison, we also performed the 100 ns CPT simulations for EctopoIcc only. The
blue colored lines in Figures 4A and 4B correspond to measurements for EctopoIcc only for
the same 100 ns simulation time as for the ternary complex.
We have also calculated the binding free energy for NSC76027 binding to EctopoIcc using
simulation trajectories with MM/GBSA approach and obtained a favorable binding energy
of −35.1±7.1 kcal/mol for the binding. Here the average±s.d. values are obtained from the
binding free energy calculated for each frame. Figure 5 depicts the ternary complex, after
100 ns of MD simulations, zoomed within the EctopoI-ssDNA binding interface.

Author Manuscript

Our 100 ns of CPT simulation result shows that NSC76027 forms hydrogen bonds with
EctopoI. There are three hydrogen bonds formed between NSC76027 and EctopoI residues
(ARG369, HIS365, and GLU366) with more than 50% occupancy (Table S1, Supporting
Information, Section S6) of the simulation frames. A representative 2-D interaction diagram
for formation of these hydrogen bonds are shown in Figure 6. Figure S2 (Supporting
Information, Section S6) shows such 2-D representations at 50 ns, 75 ns, and 100 ns of the
simulation time. As shown in Figure 6, there is a hydrogen bond formation between
NSC76027 and EctopoI (ARG161) but this bond was not as stable (less than 10%
occupancy) as compared to other three hydrogen bonds mentioned above.
Cell-based Assays

Author Manuscript

We conducted microbiological assays to measure the antibacterial activity of NSC76027. We
could not detect antibacterial activity against E. coli MG1655, likely because of difficulty in
penetration of this Gram-negative bacterium, or efflux pump action. Previous genetic studies
have shown that topoI is essential for the viability of mycobacteria and a validated target for
the discovery of new anti-tubercular drugs. [9c, 29] We found that NSC76027 inhibits the
growth of M. smegmatis (MIC=25 μM) and M. tuberculosis H37Rv (MIC=35 μM).
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Discussion
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DNA topoisomerases change the topological state of DNA, which is important for key
cellular processes. Bacterial DNA topoisomerases are major target biomolecules for the
discovery of new antibacterial drugs.[3] It has been shown that the accumulation of bacterial
topoIcc leads to the bacterial cell death.[7a] The inhibition of type IIA bacterial
topoisomerases as well as type IB HtopoI and type IIA human topoisomerase using poison
inhibitors are very important in the discovery of antibacterial or anticancer therapeutics.[3]
Herein, we are motivated to design a model and develop procedures to handle the covalent
complex between bacterial DNA topoI and DNA for computation-based investigations using
the CHARMM36 force field, which to the best of our knowledge, have not been conducted
previously. For structure-based drug development targeting DNA topoisomerases using
computational methods, it is crucial to investigate such a covalent complex. The action of
small molecules acting as bacterial topoI poison inhibitors can potentially lead to discovery
of new antibacterial drugs. MD simulations is helpful to visually confirm the stability of the
topoI-SM-DNA ternary complex, which is essential for the inhibitor to be a poison inhibitor
of bacterial topoisomerase as well as allows the investigation of target-inhibitor interactions
for the stability of the bacterial topoI-SM-DNA ternary complex. As a model system, we
have considered EctopoI, which is the most extensively studied bacterial topoI for the
discovery of antibacterial drugs.
We have used TYDN.rtf and TYDN.prm files together with standard CHARMM36m force
field to establish the covalent linkage between OS319 and C5′
9 (Figure 1), minimize the

Author Manuscript

structure for target used in VS, and perform MD simulation of the ternary complex. These
two topology and parameter files (TYDN.rtf and TYDN.prm, Supporting Information,
Sections S1 and S2) are easy to use and the idea that we adopted to establish EctopoI
covalent linkage with ssDNA (between OS319 and C5′
9 ) is very straightforward.

Author Manuscript

Since topoI forms a transient covalent linkage with a single DNA strand, the EctopoIcc
target enhances the significance of screening results. Taking this into account, we minimized
the EctopoIcc structure (Section 2.3) using TYDN.rtf and TYDN.prm files (Supporting
Information, Sections S1 and S2). The minimized EctopoIcc was then used as the screening
target. We then performed VS of NCI DTP library of SMs against this minimized EctopoIcc
target. From the minimized structure, the protein coordinates were also used to generate
PDBQT files for EctopoI only conformation and perform an independent screening of the
same SMs against this EctopoI only target. Out of 2263 SMs, 2008 SMs successfully passed
through screening resulting output files with affinity values. This discrepancy might be due
to poor structural transformation (from 2-D to 3-D) of remaining SMs. We selected one of
the top hit SMs, NSC76027, as a model SM for further investigations. We expect that
NSC76027 will recognize EctopoI to inhibit the DNA relaxation. We have carried out a
series of SPR experiments to demonstrate favorable binding of NSC76027 with EctopoI as
well as relaxation inhibition assays to demonstrate the inhibition of EctopoI relaxation
activity. These experimental results confirm on one hand that NSC76027 specifically binds
to EctopoI and on the other hand it prevents the DNA relaxation activity of EctopoI with
clear dose dependence. A scheme of both computational as well experimental procedures
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that we followed to carry out our investigations is shown in the Supporting Information
(Figure S4, Section S7). We could not detect specific interaction between NSC76027 and
ssDNA fragments for our 100 ns CPT simulation time. The simulation time used here might
not be long for enough structural rearrangements in EctopoIcc structure to allow the
formation of hydrogen bonds between NSC76027 and ssDNA. It is also possible that
NSC76027 binds to EctopoI to prevent the formation of the complex with DNA.
Mechanistic and structural studies in future experiments will address this interaction
mechanism.

Author Manuscript

The optimized NSC76027 confirmation was used to establish the ternary complex and the
ternary complex was simulated for 100 ns under CPT conditions. The covalent linkage was
stable for 100 ns of the simulation time. Biomolecular interfaces are the area where small
molecules have binding preference, establishing interfacial interactions, due to imperfection
of packing at the interface.[30] It has also been found that some interfacial residues, with
higher probability of being pocket residues, have only a smaller fraction of their surface area
accessible to solvent and are promising ligand binding sites.[31] Such interfacial
interaction[32] may promote the trapping of EctopoIcc by forming a stable ternary complex.
The accumulation of these ternary complexes in bacterial cell ultimately may lead to the
bacterial cell killing.

Author Manuscript
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There are many libraries of SMs available for virtual screening. In this report, we only
intend to demonstrate the usefulness of our model for molecular simulations that handles
bacterial topoIcc, which has importance in new antibacterial drug development. Besides,
implementation of additional filters to the solubility filter may allow selection of the
molecules with adequate permeability. Furthermore, there are different subfamilies of DNA
topoisomerases that form covalent complexes with single or double strands of DNA.
However, the formation of the covalent complexes all involve the covalent linkage of active
site tyrosine with the DNA phosphate at the cleavage site that our model is capable of
handling. We believe that our method and procedures described in this report may be utilized
for the covalent complex of other DNA topoisomerases and single or double stranded DNA,
including HtopoI that is one of the targets for anticancer drug development. We have
generated HtopoIcc following our approach and preformed a short simulation for this
structure using a slightly modified TYDN.rtf and TYDN.prm (Supporting Information,
Sections 1 and 2) files together with CHARMM36m force field. The modification was
needed to handle tyrosine-DNA covalent bond at 3’ DNA end. Indeed, our approach works
for this system as well. Future investigations, including longer simulations, for HtopoIcc will
be carried out. Our procedure is therefore an important step in computer aided structurebased drug development that requires investigations of both topoI-DNA covalent complex
both in presence and absence of hit SMs. Based on results presented in this manuscript,
several avenues will open for future mechanistic studies in expanding the current
investigations or exploration of new drug candidates.

Conclusions
Trapping transient covalent complex of DNA topoI and DNA in bacterial cells using topoI
poison inhibitors leads to accumulation of such complexes, which ultimately kills the
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bacterial cells. Computational investigations, including MD simulations, of small molecules
as bacterial topoI poison inhibitors requires handling of the covalent complex of bacterial
topoI and DNA, which, to the best of our knowledge, has not been previously reported.
Motivated by this, we designed the topoI-DNA covalent complex model and performed MD
simulations to investigate the dynamics of the ternary complex. Our EctopoI-DNA covalent
complex model is relatively simple and the procedures described here are straightforward to
implement in other topoisomerase systems, including HtopoI.

Experimental Section
Wild type EctopoI-ssDNA structure set up:

Author Manuscript

PDB IDs 3PX7[10a] and 4RUL[10b] were used to model a full length EctopoIcc. Notably,
4RUL is a full length EctopoI in complex with ssDNA whereas 3PX7 is a shorter sequence
of EctopoI covalently bound to ssDNA. Hence, to get the full length EctopoI in covalent
complex with ssDNA, we structurally aligned the 4RUL structure over 3PX7 and saved the
CTD from the aligned 4RUL. This aligned CTD was connected to 3PX7. Therefore, 4RUL
is the template for the CTD. We also manually added missing DNA nucleotides in 3PX7
with the same nucleotides in 4RUL, using VMD. Missing residues were completed using
MODELLER[33] with replacing the phosphotyrosine (PTR) engineered residue (residue ID
319) in 3PX7 by tyrosine and the mutated amino acid residue N111 in 3PX7 was also
converted back to D111 using CHARMM-GUI[34] to have EctopoI in its wild-type form.
The missing ssDNA nucleotides in 3PX7 were also added using VMD[35] The resulting
structure has Zn2+ but no Hg2+ atoms. PDB ID 1K4T[26] was used to model and simulate
the HtopoIcc.

Author Manuscript

Generation of EctopoI-DNA covalent complex (EctopoIcc):

Author Manuscript

Energy minimization:

The ssDNA nucleotides in the full length EctopoIcc, after adding the missing nucleotides in
crystal structure 3PX7, are present as 5’AATGCGCT↓ TTGGG3’, where the arrow shows
the ssDNA cleavage site. In this manuscript, the ssDNA nucleotides or atoms in these
nucleotides will be identified as their position (from 5’ to 3’) along with their names. Using
VMD[35] and CHARMM36m force field as well as the TP1 phosphotyrosine patch together
with a topology file (TYDN.rtf, Supporting Information, Section S1), first Y319 was
phosphorylated and then a linkage between phosphorylated Y319 in EctopoI and 5’ ssDNA
end was established. The resulting structure and data files (.psf and .pdb files) now have
EctopoI-ssDNA covalent linkage. Slightly modified TYDN.rtf (Supporting Information,
Section S1) was used to generate the HtopoIcc.

EctopoIcc was solvated using VMD in a cubic box of dimension 140×140×140 Å3 with
TIP3 water and then electrically neutralized with NaCl and NaCl concentration was set to 50
mM. The resulting system comprised of 261,332 atoms. The energy minimization was
carried out for 10,000 steps using NAMD package[36] with parameters in CHARMM36m
force field together with parameters in TYDN.prm (Supporting Information, Section S2),
using the conjugate gradient and line search algorithm. We used the Particle Mesh Ewald
(PME)[37] method for the long-range interactions with 12Å non-bonded cut-off. Slightly
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modified TYDN.prm (Supporting Information, Section S2) was used to minimize the
HtopoIcc.
Virtual screening (VS):
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Open Babel[38] was used to generate ligand input files (PDBQT files). Briefly, twodimensional structures of NCI DTP library SMs (Diversity Set V, Mechanistic Set IV,
Approved Oncology Drugs Set VI, and Natural Products Set III) were converted to threedimensional (3-D) structures and then to PDBQT file formats. We selected only 2263
soluble SMs from the entire set of SMs. These 3-D structures were minimized for 10,000
steps using obminimize and then random ligand conformer of each minimized SM was
generated using obconformer in Open Babel followed by conversion to PDBQT files with
addition of polar hydrogen atoms. The minimized EctopoIcc as well as EctopoI coordinates
extracted from the same EctopoIcc were converted to PDBQT files using
AutoDockTools[39] (version 1.5.6) with addition of polar hydrogen atoms to use as the
screening targets. Finally, AutoDock Vina[40] (version 1.1.2) was used in VS of ligands
against the targets. The screening was performed using a search box with dimensions
118×80×84 Å3, which covered the entire EctopoIcc or EctopoI. The docked positions of top
ranked SMs for EctopoIcc with affinity greater than −10 kcal/mol were examined for being
near our target area, the Y319 cleavage site. We also examined the docked position of the
selected SMs to determine whether they are docked nearby the Y319 site in the EctopoI only
target with equal or no less than 90% affinities as compared to the docked affinities with
EctopoIcc. The selected SMs with higher affinity values were first ranked based on affinity
for EctopoIcc and then ranked again based on affinity for EctopoI only.
Surface plasmon resonance (SPR):
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Biacore T200 SPR instrument (GE Healthcare) was used to carry out the SPR experiments.
EctopoI was immobilized as a ligand on a CM5 chip (GE Healthcare) to a level of ~20,000
Response Units (RU) in the presence of 10 mM sodium acetate buffer at pH 5.5. Ezrin was
also immobilized as a control ligand. A standard amine coupling chemistry according to the
manufacturer’s recommended protocol (GE Healthcare) was used to capture ligands. PBS-P
+ (0.2 M phosphate buffer, pH 7.4, 27 mM KCl, 1.37 M NaCl, and 0.5% v/v surfactant P20)
buffer was diluted 10X in ddH2O and filtered through a 0.22 μM polystyrene membrane
filter (referred to as PBS-P hereafter) and then used as the immobilization running buffer.
NSC76027, one of the hit SMs used as analyte, was injected over the ligand immobilized
CM5 chip surfaces in various concentrations in the presence of the PBS-P buffer and
supplemented with 1% v/v DMSO and filtered through a 0.22 μM polystyrene membrane
(referred to as PBSP+1%DMSO hereafter). The same PBS-P+1% DMSO buffer was used as
the running buffer in the analyte-ligand binding experiments. NSC14975 was also used as a
negative control analyte. A 1:1000 (v/v) H3PO4 solution (H3PO4:ddH2O) or 2 M NaCl was
used to regenerate the CM5 chip sensor surface (injected for 20 s). A flow rate of 30 μL/min
or 50 μL/min was maintained during analyte injections and the regeneration solutions. One
flow cell (FC) was used for reference (RFC) and another FC next to the RFC of the same
CM5 chip was used as an active FC (AcFC). Analyte solutions were injected on both FCs in
duplicate for each concentration. The RFC has the same surface chemistry as the AcFC but
immobilized ligands (EctopoI or Ezrin). SPR sensorgrams for PBS-P+1% only injections
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were also recorded for blank subtraction. The sensorgrams obtained for analysis were both
reference (signals from RFC) and blank (signals for PBS-P+1% DMSO only) subtracted.
Relaxation inhibition assay:
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Recombinant EctopoI, expressed in E. coli, was purified as described previously.[41]
EctopoI relaxation activity inhibition by NSC76027 was assayed in a buffer containing 10
mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg/ml gelatin, and 0.5 mM MgCl2. Half a
microliter of NSC76027 dissolved in DMSO or solvent alone was mixed with 10 μl of the
reaction buffer containing 10 ng of enzyme before the addition of 9.5 μl of reaction buffer
containing 160 ng of supercoiled pBAD/Thio plasmid DNA purified by cesium chloride
gradient as the substrate. Following incubation of the mixtures at 37°C for 30 min, the
reactions were terminated by the addition of 4 μl of 50% glycerol, 50 mM EDTA, and 0.5%
(v/v) bromophenol blue and the mixtures were analyzed by agarose gel electrophoresis. The
gels were stained in ethidium bromide and photographed under UV light.
Molecular dynamics (MD) simulations:
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LigParGen webserver[42] was used to generate topology and parameter files of the
NSC76027 optimized structure (NSC76027 input files). All-atom MD simulations were
performed using the NAMD simulation package[36] for EctopoIcc alone and the ternary
complex. The input files (.psf and .pdb files) for MD simulations were generated by using
VMD [37] with CHARMM36m force field together with TYDN.rtf (Supporting
Information, Section S1) and the NSC76027 input files. The EctopoIcc and ternary complex
structures were solvated using VMD[35] in a cubic box of dimension 140×140×140 Å3 with
TIP3 water and then electrically neutralized by adding NaCl and NaCl concentration was set
to 50 mM. The resulting EctopoIcc and ternary complex system comprised of 261,332 and
261,150 atoms, respectively. This ternary complex structure has the EctopoI-ssDNA
covalent linkage generated using the same procedures as mentioned in the Experimental
section, with no covalent bonding of NSC76027 with EctopoI and ssDNA. The EctopoIcc
and ternary complex systems were minimized for 10,000 steps. CHARMM36m force field
parameter files, TYDN.prm file (Supporting Information, Section S2), and parameter file
from the NSC76027 input files were used to minimize the complex structures. The
minimized complex structures were then equilibrated at 300 K (27 °C) for 100 ps with
protein heavy atoms harmonically restrained at a 1 fs integration time step. Finally, the
simulations were propagated with Langevin dynamics with a damping constant of 1 ps−1 for
100 ns under CPT condition with a time step of 2 fs for 100 ns. MD simulations for
HtopoIcc were carried out using a slightly modified TYDN.prm file, for 3’ DNA end,
together with the same CHARMM36 force field parameter files as mentioned above.
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Cell-based Assays:

M. smegmatis mc2155 cells were grown first at 37 °C in 7H9 media supplemented with
0.2% glycerol, 0.05% Tween 80, and 10% albumin, dextrose, sodium chloride (ADN) to
saturation and then diluted 1:50 in 7H9 without ADN. After growing overnight to saturation
again, cells adjusted to OD600 =0.1 were diluted 1:5 in 7H9 media. Aliquots of 50 μL of the
diluted cells corresponding to ~106 cells were then added to a clear-bottom 96-well plate
that contained 50 μL of the serially diluted compound in 7H9 media. Resazurin was
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added[43] in a final concentration of 0.02% to all the wells of the plate after 48 hours of
incubation, and fluorescence readings at λex 528/20 and λem 590/35 were obtained to
determine the Minimum Inhibitory Concentration (MIC) values. The MIC was recorded as
the concentration that prevented at least 90% growth when compared to the control wells
with DMSO. Antibacterial activity against E. coli MG1655 was assayed in Müller–Hinton
broth (MHB). MIC against M. tuberculosis were determined by a modified microplate
Alamar blue assay (MABA) as a service provided by the Institute for Tuberculosis Research
at University of Illinois at Chicago.
Data Analysis:
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Images of agarose gels from the relaxation inhibition assay were analyzed using AlphaView
software (San Jose, CA) to quantitate the supercoiled DNA bands. Inhibition was calculated
as the percentages of supercoiled DNA that was not relaxed in the presence of different
concentrations of NSC76027. The non-linear fitting of in vitro relaxation inhibition data
using four-parameter variable slope model was accomplished by GaphPad prism (La Jolla,
CA). Biacore T200 evaluation software version 1.0 (GE Healthcare) was used to visualize
the SPR sensorgrams and generate data for plotting. VMD[35] was used to analyze
simulation trajectories, to determine radius of gyration of NSC76027, to measure RMSD
values, and to visualize as well as generate pictures of structures. Calculation of binding free
energy using MM/GBSA approach was performed using NAMD. Each frame in the NVT
simulation trajectory file was saved at every 200 ps. Carma[44] was used to determine
massweighted radius of gyration (Rg) of the simulation trajectories. An atomic distance of
3.5Å and angle cut off of 30 degrees were used to trace hydrogen bonding, using VMD.[35]
2-D ligand interaction maps were generated using Schrödinger Maestro.[45] GaphPad prism
was used to draw graphs.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Covalent linkage between EctopoI and ssDNA generated using our procedure. The
nucleophile, Y319 of EctopoI upon phosphorylation, is represented within a dotted circle.
One of the side chain oxygen atoms of the phosphorylated Y319 (OS319) is linked with 5’
carbon of thymine in the 9th position (C5′
9 ) of the ssDNA via a covalent bond.
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Figure 2.
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A) SPR sensorgrams obtained in the selective binding test for NSC76027. SPR sensorgrams
from dose response assays for: B) NSC76027 and C) NSC14975 binding to EctopoI. D)
NSC76027 binding to EctopoI and Ezrin at different NSC76027 concentrations. The two
continuous lines with the same color correspond to the SPR sensorgrams for the same
concentrations recorded in duplicate for technical reproducibility and the dashed lines
indicate fitting of experimental sensorgrams to a 1:1 kinetics binding model.
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Figure 3.
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A) Inhibition of EctopoI relaxation activity by NSC76027. Serial two-fold dilutions of
NSC76027, starting with 8 μM in lane 3 and ending with 62.5 nM in lane 10. Lanes 1,
control reaction mixture with no enzyme added; lanes 2, DMSO control. S: Supercoiled
DNA, N: Nicked DNA, FR: Fully Relaxed DNA, PR: Partially relaxed DNA. C) IC50 of
NSC76027. Symbols are the average percentage inhibition values from four different
experiments with standard deviations shown as error bars. The red continuous line is the
four-parameter variable slope non-linear fit to determine IC50 value, which is ~2.2 μM. C)
Serial two-fold dilutions of NSC14975 (negative control analyte), starting with 125 μM in
lane 9 and ending with 1.95 μM in lane 3. Lane 1: control reaction mixture with no enzyme
added, lane 2: DMSO control, lane 10: 25 μM NSC76027.
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Figure 4.
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A) RMSD measurements and B) Radius of gyration (Rg) of the ternary complex (EctopoINSC76027-ssDNA) structures obtained over the time course of MD simulations. The RMSD
and Rg measurements for EctopoIcc are also shown for comparison.
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Figure 5.
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The ternary complex after 100 ns of MD simulations zoomed near the ssDNA cleavage site.
Grey colored structure represents EctopoI with colored CPK structure as Y319 in covalent
complex with ssDNA, red colored structure represents ssDNA, and colored licorice structure
represents NSC76027.
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Figure 6.

Representative 2-D interaction diagram showing formation of hydrogen bonds between
NSC76027 and EctopoI at 25 ns. The arrows that connect NSC76027 atoms with EctopoI
residues represent the hydrogen bonds.
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